IMPACT-HTA multicriteria value framework
A structured method to assess health technologies by combining multiple factors like effectiveness, cost, patient impact, and broader societal values into an overall value judgment.
At a glance
Use when
Assessing innovative or high-cost therapies; evaluating treatments for rare diseases; when traditional cost-effectiveness analysis is insufficient; need for inclusive, transparent decision processes.
Avoid when
Rapid assessment is required with limited data; when only head-to-head clinical trial data is available without broader context; in systems with rigid, purely economic decision rules.
Inputs
Scores and weights for predefined criteria across clinical, economic, patient, and societal domains; input from stakeholders including clinicians, patients, and payers.
Outputs
A composite value score for a health technology; a transparent rationale for the assessment; comparative analysis across technologies.
How it works
A multicriteria decision analysis (MCDA) framework developed within the IMPACT-HTA project that enables systematic, transparent weighting and scoring of diverse criteria across clinical, economic, patient-reported, and societal domains to inform HTA decisions.
- Project
- IMPACT HTA
- Funding
- Horizon 2020
- Project status
- Completed 2021
- HTA domains
- Aspects Beyond HTA
- Categories
- Appraisal
- Technology
- Medicines
- Assumptions
- Relevant criteria can be defined and measured; stakeholders can provide meaningful weights; value is multidimensional and not captured by cost-effectiveness alone; transparency improves legitimacy of decisions.
- Strengths
- Comprehensive and transparent; incorporates diverse perspectives including patients; allows comparison across different types of technologies; supports structured decision-making in complex cases.
- Limitations
- Requires significant stakeholder input and resources; weighting can be subjective; implementation in real-world HTA processes may be challenging; not all criteria are easily quantifiable.
- Also known as
- IMPACT-HTA MCDA, IMPACT-HTA framework
Questions this answers
- › How can we compare new health technologies when they differ in effectiveness, cost, and impact on patients' lives?
- › What factors beyond just clinical benefit and cost should be considered in health technology assessment?
- › How can patient and societal values be formally included in decisions about which treatments to fund?
- › How can decision makers be more transparent about how they weigh different aspects of a technology's value?
- › Can we create a fairer system for assessing treatments for rare diseases or high unmet need?
- › How do we combine expert and patient input when evaluating a new therapy?
References & sources
- deliverableec.europa.eu ↗
Related methods
Similar by meaning
- We need to talk about values: framework for articulating normative reasoning in HTA
- A Health Economics Approach to US Value Assessment Frameworks
- HTA appraisal framework for rare disease treatments
- INTEGRATE-HTA Model
- Key Principles for the Improved Conduct of Health Technology Assessments for Resource Allocation Decisions
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.